- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
ProQR Therapeutics NV (PRQR)
ProQR Therapeutics NV stock price live, this page displays NASDAQ PRQR stock exchange data. View the PRQR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the ProQR Therapeutics NV real time stock price chart below.
What Is the ProQR Therapeutics NV Stock Price Today?
The ProQR Therapeutics NV stock price today is 1.563.
What Is the Stock Symbol for ProQR Therapeutics NV?
The stock symbol for ProQR Therapeutics NV is "PRQR."
What Stock Exchange Does ProQR Therapeutics NV Trade On?
ProQR Therapeutics NV is listed and trades on the NASDAQ stock exchange.
Is ProQR Therapeutics NV a Good Stock to Buy?
Determining whether ProQR Therapeutics NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PRQR quote. (ISIN: NL0010872495)
What Is the ProQR Therapeutics NV Stock Price Today?
The ProQR Therapeutics NV stock price today is 1.563.
What Is the Stock Symbol for ProQR Therapeutics NV?
The stock symbol for ProQR Therapeutics NV is "PRQR."
What Stock Exchange Does ProQR Therapeutics NV Trade On?
ProQR Therapeutics NV is listed and trades on the NASDAQ stock exchange.
Is ProQR Therapeutics NV a Good Stock to Buy?
Determining whether ProQR Therapeutics NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PRQR quote. (ISIN: NL0010872495)
1.565
-0.065(-3.99%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.560
1.660
52 wk Range
1.330
3.100
Earnings results expected in 6 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.5601.660
52 wk Range
1.3303.100
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PRQR Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
8.875
Upside
+467.09%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
ProQR Therapeutics NV SWOT Analysis
RNA Editing Pionee | ProQR Therapeutics leads in RNA editing technology, targeting cholestatic diseases and MASH with its innovative Axiomer platform and expanding clinical pipeline |
Financial Stability | $143M cash position sustains operations until mid-2027, with analyst price targets ranging from $4 to $14, suggesting significant upside potential |
Strategic Partnerships | Collaboration with Eli Lilly bolsters credibility and valuation, while diverse pipeline across multiple therapeutic areas showcases platform versatility |
Clinical Milestones | AX-0810's Phase 1 trial initiation marks a crucial step, with data expected in Q4 2025 potentially validating the RNA editing approach and derisking the platform |
Compare PRQR to Peers and Sector
Metrics to compare | PRQR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPRQRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.4x | −3.5x | −0.4x | |
PEG Ratio | 0.14 | −0.02 | 0.00 | |
Price/Book | 2.9x | 1.6x | 2.6x | |
Price / LTM Sales | 8.7x | 18.1x | 3.2x | |
Upside (Analyst Target) | - | 150.4% | 46.7% | |
Fair Value Upside | Unlock | 0.5% | 7.6% | Unlock |
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 8.875
(+467.09% Upside)
Earnings
Latest Release
Mar 12, 2026
EPS / Forecast
-0.08 / -0.10
Revenue / Forecast
4.71M / 4.38M
People Also Watch
FAQ
What Is the ProQR Therapeutics NV (PRQR) Stock Price Today?
The ProQR Therapeutics NV stock price today is 1.565 USD.
What Stock Exchange Does ProQR Therapeutics NV Trade On?
ProQR Therapeutics NV is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for ProQR Therapeutics NV?
The stock symbol for ProQR Therapeutics NV is "PRQR."
What Is the ProQR Therapeutics NV Market Cap?
As of today, ProQR Therapeutics NV market cap is 166.470M USD.
What Is ProQR Therapeutics NV's Earnings Per Share (TTM)?
The ProQR Therapeutics NV EPS (TTM) is -0.401.
When Is the Next ProQR Therapeutics NV Earnings Date?
ProQR Therapeutics NV will release its next earnings report on Apr 30, 2026.
From a Technical Analysis Perspective, Is PRQR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has ProQR Therapeutics NV Stock Split?
ProQR Therapeutics NV has split 0 times.
How Many Employees Does ProQR Therapeutics NV Have?
ProQR Therapeutics NV has 187 employees.
What is the current trading status of ProQR Therapeutics NV (PRQR)?
As of Apr 24, 2026, ProQR Therapeutics NV (PRQR) is trading at a price of 1.565 USD, with a previous close of 1.630 USD. The stock has fluctuated within a day range of 1.560 USD to 1.660 USD, while its 52-week range spans from 1.330 USD to 3.100 USD.
What Is ProQR Therapeutics NV (PRQR) Price Target According to Analysts?
The average 12-month price target for ProQR Therapeutics NV is 8.875 USD, with a high estimate of 14 USD and a low estimate of 4 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +467.09% Upside potential.
What Is the PRQR Premarket Price?
PRQR's last pre-market stock price is 1.640 USD. The pre-market share volume is 1,280.000, and the stock has decreased by 0.010, or 0.610%.
What Is the PRQR After Hours Price?
PRQR's last after hours stock price is 1.680 USD, the stock has decreased by 0.050, or 3.070%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.